Evidence map›Paper›PMID 37232839›Full record

ArticleCurrent oncology (Toronto, Ont.)2023

Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on "Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain.

Daniel Rayson, Sonal Gandhi, Anil A Joy, Christine Brezden-Masley, Karen A Gelmon, Sandeep Sehdev, David Cescon, Stephen Chia

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Daniel RaysonDivision of Medical Oncology, Department of Medicine, Queen Elizabeth II Health Sciences Center, Halifax, NS B3H 2Y9, Canada.
Sonal GandhiDivision of Medical Oncology/Hematology, Odette Cancer Centre Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
Anil A JoyDivision of Medical Oncology, Cross Cancer Institute, Edmonton, AB T6G 1Z2, Canada.
Christine Brezden-MasleyDivision of Medical Oncology, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada.ORCID 0000-0002-4818-318X
Karen A GelmonDivision of Medical Oncology, British Columbia Cancer Centre, Vancouver, BC V5Z 4E6, Canada.
Sandeep SehdevDepartment of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada.
David CesconDepartment of Medical Oncology, University Health Network, Toronto, ON M5G 1Z5, Canada.
Stephen ChiaDivision of Medical Oncology, British Columbia Cancer Centre, Vancouver, BC V5Z 4E6, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We appreciate the opportunity to respond to the comment [...].

Indexed as

Breast NeoplasmsAdvisory CommitteesAntibodies, Monoclonal, HumanizedCanadaErb-b2 Receptor Tyrosine KinasesFemaleHumansNeoadjuvant TherapyTrastuzumabAntibodies, Monoclonal, HumanizedErb-b2 Receptor Tyrosine KinasespertuzumabTrastuzumab

Identifiers

PMID37232839
PMCPMC10217302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.